A Phase 3 interventional study of Avatrombopag and Placebo Oral Tablet in Chemotherapy-induced Thrombocytopenia, sponsored by Sobi, Inc.. Completed at 55 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-28.
Sponsored by Sobi, Inc. · Phase 3, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing avatrombopag in Thrombocytopenia — 6 open to participants now, 6 under way, 2 of them phase 3. avatrombopag · Thrombocytopenia.
Among the 23 studies testing avatrombopag in Thrombocytopenia, this one is the 8th largest by enrollment, is one of 2 that started in 2018, is one of 5 in phase 3, and was the 8th registered.
484 studies on the registry are indexed under Thrombocytopenia; 102 are open to participants now.
Browse Thrombocytopenia studies →6 of the 23 studies testing avatrombopag in Thrombocytopenia are open now, in 3 countries. Recruiting first, the newest first:
Al-Mustansiriyah University · Sites in Iraq
Ages 18+
Peking University People's Hospital · Sites in China
Ages 18–65
Second Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
University of Virginia · Sites in United States
Ages 18+
By country, each count listing its studies:
avatrombopag: first FDA approval 2018 (DOPTELET), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 3 6 · Phase 4 4
First in 2009; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 122 is above the median of 54 across 336 interventional studies indexed under Thrombocytopenia.
Median enrollment 50 across the 23 interventional studies. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 23 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sobi, Inc., one of the names counted as Swedish Orphan Biovitrum. Under that name alone:
Sobi, Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
Swedish Orphan Biovitrum has 5 studies filed under Thrombocytopenia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 23 studies testing avatrombopag in Thrombocytopenia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of avatrombopag in subjects with chemotherapy-induced thrombocytopenia receiving chemotherapy for the treatment of ovarian, lung (small cell and non-small cell) and bladder cancer.
Subjects will receive placebo controlled test treatment for one cycle of chemotherapy followed by an observational cycle. Subjects will have the option to continue into an open label extension period for all remaining chemotherapy cycles within the current regimen. After the follow-up visit, all subjects will continue to a long-term safety follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participant receiving a chemotherapy regimen given in a 21 or 28-day cycle, including 1 or more of the following agents or class of agents:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study is 2:1 randomization ratio (avatrombopag to placebo). Investigational product administered orally once daily for 5 days prior to chemotherapy and 5 days following chemotherapy treatment.
Drug: Avatrombopag
Study is 2:1 randomization ratio (avatrombopag to placebo). Investigational product administered orally once daily for 5 days prior to chemotherapy and 5 days following chemotherapy treatment.
Drug: Placebo Oral Tablet
Oral avatrombopag tablet
Placebo comparator tablet
Percentage of Subjects Who do Not Require Platelet Transfusion, Dose Reduction in Chemotherapy by 15%, or Chemotherapy Delay by >=4 Days
Time frame: Randomization up to 33 days
Duration of Severe Thrombocytopenia Defined as a Platelet Count <50 x 10^9/L
The duration of severe thrombocytopenia is defined as the total number of days with a platelet count \<50×10\^9/L during the period after post-chemotherapy study drug treatment in Cycle X+1 through Chemotherapy Day of Cycle X+2.
Time frame: Randomization up to 33 days
Change in Platelet Count From Baseline (Nadir)
Comparison of avatrombopag 60 mg vs. placebo, adjusted for the number of chemotherapy agents currently receiving per IWRS (1, ≥2). Cycle X nadir is defined as the lowest platelet count value prior to the first dose of study drug; Cycle X+1 nadir is defined as the lowest platelet count value during the period after post-chemotherapy study drug treatment in Cycle X+1 through Chemotherapy Day in Cycle X+2.
Time frame: Randomization up to 33 days
Percentage of Subjects Who Did Not Have Major or Non-major Clinically Relevant Bleeding During the Period After Post-chemotherapy Study Drug Treatment in Cycle X+1 Through Chemotherapy Day of Cycle X+2.
Time frame: Randomization up to 33 days
This was a Phase 3, randomized, double- blind, placebo controlled study of the efficacy and and safety of avatrombopag in subjects with chemotherapy induced thrombocytopenia and non active non-hematologic cancers. The study was conducted by qualified investigators at 71 sites in China, Hungary, Poland, Russia, Serbia, Ukraine, and the United States. The first subject was enrolled 12October2018.
| Milestone | Avatrombopag | Placebo |
|---|---|---|
| Started | 82 | 40 |
| Completed | 61 | 34 |
| Not completed | 21 | 6 |
| Withdrew: Withdrawal by subject | 9 | 1 |
| Withdrew: Adverse event | 4 | 1 |
| Withdrew: Physician decision | 3 | 2 |
| Withdrew: Death | 2 | 0 |
| Withdrew: Other | 3 | 2 |
| Participants | Avatrombopag | Placebo |
|---|---|---|
| Percentage of Subjects Who do Not Require Platelet Transfusion, Dose Reduction in Chemotherapy by 15%, or Chemotherapy Delay by >=4 Days | 57 | 29 |
The duration of severe thrombocytopenia is defined as the total number of days with a platelet count \<50×10\^9/L during the period after post-chemotherapy study drug treatment in Cycle X+1 through Chemotherapy Day of Cycle X+2.
| Days | Avatrombopag | Placebo |
|---|---|---|
| Duration of Severe Thrombocytopenia Defined as a Platelet Count <50 x 10^9/L | 4.6 ± 5.53 | 4.7 ± 6.56 |
Comparison of avatrombopag 60 mg vs. placebo, adjusted for the number of chemotherapy agents currently receiving per IWRS (1, ≥2). Cycle X nadir is defined as the lowest platelet count value prior to the first dose of study drug; Cycle X+1 nadir is defined as the lowest platelet count value during the period after post-chemotherapy study drug treatment in Cycle X+1 through Chemotherapy Day in Cycle X+2.
| Platelets x 10^9/L | Avatrombopag | Placebo |
|---|---|---|
| Change in Platelet Count From Baseline (Nadir) | 51.5 ± 61.85 | 29.1 ± 39.48 |
| Participants | Avatrombopag | Placebo |
|---|---|---|
| Percentage of Subjects Who Did Not Have Major or Non-major Clinically Relevant Bleeding During the Period After Post-chemotherapy Study Drug Treatment in Cycle X+1 Through Chemotherapy Day of Cycle X+2. | 82 | 40 |
Collected over Adverse event data were collected during the Double-Blind Treatment Phase and included two 21- or 28-day chemotherapy cycles.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Avatrombopag | 2/82 (2.4%) | 16/82 (19.5%) | 71/82 (86.6%) |
| Placebo | 0/40 (0%) | 8/40 (20%) | 36/40 (90%) |
| Event | Avatrombopag | Placebo |
|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 4/82 | 4/40 |
| AnaemiaBlood and lymphatic system disorders | 1/82 | 2/40 |
| NeutropeniaBlood and lymphatic system disorders | 0/82 | 2/40 |
| PancytopeniaBlood and lymphatic system disorders | 3/82 | 0/40 |
| LeukopeniaBlood and lymphatic system disorders | 1/82 | 1/40 |
| PneumoniaInfections and infestations | 1/82 | 1/40 |
| Cerebral ischaemiaNervous system disorders | 0/82 | 1/40 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/82 | 0/40 |
| LeukocytosisBlood and lymphatic system disorders | 1/82 | 0/40 |
| StomatitisGastrointestinal disorders | 1/82 | 0/40 |
| Event | Avatrombopag | Placebo |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 32/82 | 21/40 |
| NeutropeniaBlood and lymphatic system disorders | 24/82 | 17/40 |
| LeukopeniaBlood and lymphatic system disorders | 24/82 | 15/40 |
| ThrombocytopeniaBlood and lymphatic system disorders | 15/82 | 13/40 |
| NauseaGastrointestinal disorders | 6/82 | 6/40 |
| ThombocytosisBlood and lymphatic system disorders | 9/82 | 2/40 |
| AstheniaGeneral disorders | 5/82 | 4/40 |
| FatigueGeneral disorders | 3/82 | 3/40 |
| VomitingGastrointestinal disorders | 5/82 | 0/40 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 4/82 | 2/40 |
| Age, Continuous(years) | Avatrombopag | Placebo | Total |
|---|---|---|---|
| Age at Enrollment | 61.0 ± 10.08 | 60.8 ± 10.41 | 61.0 ± 10.15 |
| Sex: Female, Male(Participants) | Avatrombopag | Placebo | Total |
|---|---|---|---|
| Female | 43 | 22 | 65 |
| Male | 39 | 18 | 57 |
| Ethnicity (NIH/OMB)(Participants) | Avatrombopag | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 78 | 37 | 115 |
| Unknown or Not Reported | 4 | 3 | 7 |
| Race (NIH/OMB)(Participants) | Avatrombopag | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 5 | 3 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 77 | 37 | 114 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| ECOG Performance Status(Participants) | Avatrombopag | Placebo | Total |
|---|---|---|---|
| Subjects with ECOG Score 0 | 21 | 8 | 29 |
| Subjects with ECOG Score 1 | 60 | 31 | 91 |
| Subjects with ECOG Score 2 | 1 | 1 | 2 |
| Number of Eligible Chemotherapy Agents Currently Receiving per IWRS(Participants) | Avatrombopag | Placebo | Total |
|---|---|---|---|
| Subjects Receiving 1 Agent | 40 | 20 | 60 |
| Subjects Receiving ≥ 2 Agents | 42 | 20 | 62 |
| Baseline Platelet Count (x10⁹/L)(platelets x10⁹/L) | Avatrombopag | Placebo | Total |
|---|---|---|---|
| Mean | 29.6 ± 13.66 | 33.0 ± 11.49 | 30.7 ± 13.04 |
| Height (cm)(cm) | Avatrombopag | Placebo | Total |
|---|---|---|---|
| Mean | 166.3 ± 10.17 | 166.2 ± 10.32 | 166.3 ± 10.18 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2018 to primary completion in Aug 2020, 22 months.
Results were first posted in Nov 2021, 1 year 2 months after primary completion.
Of 29 phase 3 interventional studies under Thrombocytopenia, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 45. This study's 22 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Avatrombopag